Acute pannexin 1 blockade mitigates early synaptic plasticity defects in a mouse model of Alzheimer's disease
Author
dc.contributor.author
Flores Muñoz, Carolina
Author
dc.contributor.author
Gómez, Bárbara
Author
dc.contributor.author
Mery, Elena
Author
dc.contributor.author
Mujica, Paula
Author
dc.contributor.author
Gajardo, Ivana
Author
dc.contributor.author
Córdova, Claudio
Author
dc.contributor.author
López Espíndola, Daniela
Author
dc.contributor.author
Durán Aniotz, Claudia
Author
dc.contributor.author
Hetz Flores, Claudio
Author
dc.contributor.author
Muñoz, Pablo
Author
dc.contributor.author
González Jamett, Arlek
Author
dc.contributor.author
Ardiles, Álvaro
Admission date
dc.date.accessioned
2020-05-14T14:39:18Z
Available date
dc.date.available
2020-05-14T14:39:18Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Front. Cell. Neurosci. 14:46.
es_ES
Identifier
dc.identifier.other
10.3389/fncel.2020.00046
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/174728
Abstract
dc.description.abstract
Synaptic loss induced by soluble oligomeric forms of the amyloid beta peptide (sA beta os) is one of the earliest events in Alzheimer's disease (AD) and is thought to be the major cause of the cognitive deficits. These abnormalities rely on defects in synaptic plasticity, a series of events manifested as activity-dependent modifications in synaptic structure and function. It has been reported that pannexin 1 (Panx1), a nonselective channel implicated in cell communication and intracellular signaling, modulates the induction of excitatory synaptic plasticity under physiological contexts and contributes to neuronal death under inflammatory conditions. Here, we decided to study the involvement of Panx1 in functional and structural defects observed in excitatory synapses of the amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic (Tg) mice, an animal model of AD. We found an age-dependent increase in the Panx1 expression that correlates with increased A beta levels in hippocampal tissue from Tg mice. Congruently, we also observed an exacerbated Panx1 activity upon basal conditions and in response to glutamate receptor activation. The acute inhibition of Panx1 activity with the drug probenecid (PBN) did not change neurodegenerative parameters such as amyloid deposition or astrogliosis, but it significantly reduced excitatory synaptic defects in the AD model by normalizing long-term potentiation (LTP) and depression and improving dendritic arborization and spine density in hippocampal neurons of the Tg mice. These results suggest a major contribution of Panx1 in the early mechanisms leading to the synaptopathy in AD. Indeed, PBN induced a reduction in the activation of p38 mitogen-activated protein kinase (MAPK), a kinase widely implicated in the early neurotoxic signaling in AD. Our data strongly suggest that an enhanced expression and activation of Panx1 channels contribute to the A beta-induced cascades leading to synaptic dysfunction in AD.
es_ES
Patrocinador
dc.description.sponsorship
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT), CONICYT FONDECYT: 11150776.
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT),CONICYT FONDECYT: 11180731, 11160760, 11180186.
Takeda Pharmaceutical Company Ltd: P09-022-F, P09-015-F
PAI: 79150045.
Alzheimer's Association Research Grant: 2018-AARG-591107.
FONDAP (Comision Nacional de Investigacion Cientifica y Tecnologica): 15150012.
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT), CONICYT FONDEF: ID16I10223.
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT): 441921/2016-7, REDI170583, PMI-UVA 1402.